Hemodialysis-related Glycemic Disarrays Proven by Continuous Glucose Monitoring; Glycemic markers and Hypoglycemia.

Supplementary Appendix

Table of content

List of Principal Investigators.

Akinori Hayashi	-Department of Laboratory Medicine, Kitasato University School of Medicine -Department of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine
Naoya Shimizu	-Department of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine
Agena Suzuki	-Department of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine
Kenta Matoba	-Department of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine
Akari Momozono	-Department of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine
Tsuguto Masaki	-Department of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine
Akifumi Ogawa	-Department of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine
Ibuki Moriguchi	-Sohbudai Nieren Clinic
Koji Takano	-Department of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine
Naoyuki Kobayashi	-Sohbudai Nieren Clinic
Masayoshi Shichiri	-Department of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine

Supplementary Figure S1. Time-resolved glucose monitoring during the 5 hours following the start of HD in groups that used dialysates with different glucose concentrations. Mean ± SD sensor glucose levels during and immediately after HD, using dialysate solutions containing 100 mg/dL (A), 125 mg/dL (B), or 150 mg/dL (C) glucose. All the patients underwent HD for 4 h and ate within 0.5–1 h of the end of HD.



Supplementary Figure S2. Difference of glycemic profiles on HD day among patients undergoing HD in the morning, the afternoon and night. Mean ± SD sensor glucose levels over 24-h on an HD day in 82 patients undergoing HD in the morning (A) and in 11 in the afternoon (B) and 5 in night.



Supplementary Figure S3. Mean ± SD sensor glucose levels over 24-h on non-HD day in 21 patients who showed HD-related hypoglycemia (A) and in 77 participants who did not (B).



Supplement Table S1. Univariate and multivariate correlation analysis for 48-h glycemic profile markers.

		Univariate		Multivariate			
Factors	**Parameters**	R	*P*	r^2	*β*	F	*P*
Mean SGL (mg/dL)	Sex, male/female	0.003	0.9784				
	Age (years)	-0.02	0.8310				
	Body mass index	0.17	0.1025				
	Duration of diabetes (years)*	**0.23**	**0.0235**	0.57	-0.02	0.11	0.7374
	Duration of hemodialysis (months)*	-0.0006	0.9955				
	HbA1c (%)	**0.69**	**<0.0001**	**0.48**	**1.49**	**30.26**	**<0.0001**
	GA (%)	**0.53**	**<0.0001**	**0.57**	**-1.37**	**9.11**	**0.0033**
	GA/HbA1c ratio	**0.20**	**0.0435**	**0.53**	**1.34**	**12.61**	**0.0006**
	Casual CPR (ng/mL)*	-0.10	0.4105				
SD of SGL (mg/dL)	Sex, male/female	0.09	0.4076				
	Age (years)	0.09	0.3744				
	Body mass index	-0.04	0.7136				
	Duration of diabetes (years)*	0.15	0.1386				
	Duration of hemodialysis (months)*	-0.07	0.5052				
	HbA1c (%)	**0.51**	**<0.0001**	**0.35**	**0.37**	**9.15**	**0.0032**
	GA (%)	**0.53**	**<0.0001**	**0.29**	**0.24**	**13.41**	**<0.0001**
	GA/HbA1c ratio	**0.29**	**0.0035**	0.35	0.10	0.05	0.8220
	Casual CPR (ng/mL)*	0.04	0.7222				
%CV of SGL (%)	Sex, male/female	0.12	0.2308				
	Age (years)	0.10	0.3236				
	Body mass index	-0.15	0.1545				
	Duration of diabetes (years)*	0.05	0.6597				
	Duration of hemodialysis (months)*	-0.10	0.3328				
	HbA1c (%)	0.08	0.4559				

GA (%)	**0.23**	**0.0207**	**0.05**	**0.21**	**5.54**	**0.0207**
GA/HbA1c ratio	**0.20**	**0.0487**	0.05	0.03	0.04	0.8445
Casual CPR (ng/mL)*	0.20	0.0929				

Univariate, linear regression analysis; Multivariate, stepwised multivariate analysis.
SGL, sensor glucose level; GA, glycated albumin; GA/HbA1c ratio, GA to HbA1c (%) ratio; CPR, C-peptide immunoreactivity; SD, standard deviation; %CV, coefficient of variation.